In France, Garnache-Ottou and team investigated the anti-leukemia efficacy and safety of a third generation lentiviral CD28/4-1BB CAR-T cell product targeting CD123 (CAR123), and provided strong preclinical rationale for the clinical assessment of this autologous cell therapy [57]. Here, CD28 is linked to leukemia.